Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 3/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | CALM1 | P0DP23 | 3/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12433633 | 0.86 | ESR1 (0.36) | S1PR1S1PR3S1PR5GABRA1GABRB2 | |
| SCHEMBL12433840 | 0.83 | RXRA (0.40) | S1PR1S1PR3S1PR5GABRA1GABRB2 | |
| SCHEMBL12511074 | 0.79 | — | — | |
| SCHEMBL13980134 | 0.79 | RXRA (0.35) | S1PR1S1PR3S1PR5ESR1RXRA | |
| SCHEMBL12433647 | 0.78 | FAAH (0.39) | S1PR1S1PR3S1PR5ESR1 | |
| SCHEMBL12433637 | 0.78 | GABRA1 (0.39) | S1PR1S1PR3GABRA1GABRB2ESR1 | |
| SCHEMBL14035180 | 0.77 | HMGCR (0.35) | GABRA1GABRB2FFAR4PPARDCETP | |
| SCHEMBL12984269 | 0.76 | RARB (0.44) | S1PR1S1PR3S1PR5ESR1 | |
| SCHEMBL12433601 | 0.75 | LMNA (0.36) | GABRA1GABRB2ESR1CALM1FFAR4 | |
| SCHEMBL21609905 | 0.74 | GABRA1 (0.41) | S1PR1S1PR3GABRA1GABRB2RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981486-B2 | Compound having alkyl on benzene ring, liquid crystal composition having the compound, and liquid crystal display device having the liquid crystal composition | JNC CORPORATION (JP) | 2011-07-19 | — | — | US | disclosed |
| US-7846513-B2 | Compound having alkyl on benzene ring, liquid crystal composition having the compound, and liquid crystal display device having the liquid crystal composition | CHISSO CORPORATION (JP) | 2010-12-07 | — | — | US | disclosed |
| EP-1997867-B1 | Compound having alkyl on benzene ring, liquid crystal composition having the compound, and liquid crystal display device having the liquid crystal composition | CHISSO CORP (JP) | 2010-01-06 | — | — | EP | disclosed |
| US-20090230356-A1 | COMPOUND HAVING ALKYL ON BENZENE RING, LIQUID CRYSTAL COMPOSITION HAVING THE COMPOUND, AND LIQUID CRYSTAL DISPLAY DEVICE HAVING THE LIQUID CRYSTAL COMPOSITION | CHISSO CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090230356-A1 | COMPOUND HAVING ALKYL ON BENZENE RING, LIQUID CRYSTAL COMPOSITION HAVING THE COMPOUND, AND LIQUID CRYSTAL DISPLAY DEVICE HAVING THE LIQUID CRYSTAL COMPOSITION | BRD1, CNOT1, CXCR1 | S1PR1 2876/4885S1PR3 3797/4885S1PR5 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.